Want information and resources about VENCLEXTA, the VENCOMPASS Program supports patients taking VENCLEXTA for an approved use during the ramp-up phase and throughout their therapy. Do not have insurance coverage or have financial concerns and meet certain eligibility criteria, the Genentech Patient Foundation may be able to provide free medicine.*
Full Answer
How can I get help paying for Venclexta?
VENCLEXTA Access Solutions can refer eligible patients to the Genentech Oncology Co-pay Assistance Program for help with the out-of-pocket costs associated with VENCLEXTA.* For eligible patients with commercial or public health insurance, VENCLEXTA Access Solutions offers referrals to independent co-pay assistance foundations.†
Does Genentech oncology offer co-pay assistance for Venclexta?
Getting prescribed medicines shouldn’t be one of them. The Genentech Oncology® Co-pay Assistance Program * for VENCLEXTA can help qualified, commercially insured patients with the out-of-pocket costs associated with their VENCLEXTA, GAZYVA® (obinutuzumab), or rituximab prescriptions.
Does venetoclax interact with CYP3A inhibitors?
Concomitant use of VENCLEXTA with P-gp inhibitors or strong or moderate CYP3A inhibitors increases venetoclax exposure, which may increase the risk of TLS at initiation and during the ramp-up phase, and requires VENCLEXTA dose reduction.
Can Venclexta be added to bortezomib for multiple myeloma?
In a randomized trial (BELLINI; NCT02755597) in patients with relapsed or refractory multiple myeloma, the addition of VENCLEXTA to bortezomib plus dexamethasone, a use for which VENCLEXTA is not indicated, resulted in increased mortality.
What is the Genentech Patient Foundation?
The Genentech Patient Foundation § gives free Genentech medicine to people who don’t have insurance coverage or who have financial concerns and meet eligibility criteria. Speak to a Foundation Specialist to see if you qualify. 1-866-422-2377.
Is Genentech a void program?
No party may seek reimbursement for all or any part of the benefit received through this Program. This Program is void where prohibited by law. Genentech reserves the right to rescind, revoke, or amend the Program without notice at any time. Additional eligibility criteria apply. See full terms and conditions at
What is Venclexta used for?
VENCLEXTA is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
How long before venclexta can you do P-GP?
Avoid concomitant use of VENCLEXTA with a P-gp substrate. If concomitant use is unavoidable, separate dosing of the P-gp substrate at least 6 hours before VENCLEXTA.
How long after last dose of Venclexta?
Advise females of reproductive potential to use effective contraception during treatment with VENCLEXTA and for at least 30 days after the last dose.
Does Venclexta cause TLS?
VENCLEXTA can cause rapid reduction in tumor and thus poses a risk for TLS at initiation and during the ramp-up phase in all patients. Changes in blood chemistries consistent with TLS that require prompt management can occur as early as 6 to 8 hours following the first dose of VENCLEXTA and at each dose increase.
Can you reduce the dose of Venclexta?
No dose adjustment is recommended for patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment.
Can venclexta cause fetal harm?
VENCLEXTA may cause embryo-fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with VENCLEXTA and for at least 30 days after the last dose.
What is venetoclax 2021?from news.abbvie.com
NORTH CHICAGO, Ill., July 21, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Therapy Designation (BTD) to venetoclax (VENCLEXTA ®) in combination with azacitidine for the potential treatment of adult patients with previously untreated intermediate-, high- and very high-risk myelodysplastic syndromes (MDS) based on revised International Prognostic Scoring System (IPSS-R). A BTD is intended to expedite the development and review of medications to treat a serious medical condition and is granted when preliminary clinical evidence indicates the investigational therapy may demonstrate substantial improvement over existing therapies. 1 This marks the sixth BTD granted to venetoclax.
What is Venclexta approved for?from news.abbvie.com
Food and Drug Administration (FDA) has provided full approval to VENCLEXTA® (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy. The approval is supported by data from the Phase 3 VIALE-A (M15-656) and VIALE-C (M16-043) studies and updated data from the Phase 1b M14-358 and the Phase 1/2 M14-387 studies. The FDA previously granted accelerated approval to VENCLEXTA for this indication in 2018. 5
How many patients were in the VIALE C trial?from news.abbvie.com
A total of 211 patients were enrolled and treated in the randomized, double-blind, placebo-controlled, multicenter, Phase 3 VIALE-C trial, which evaluated the efficacy and safety of VENCLEXTA in combination with LDAC (n=143) versus placebo with LDAC (n=68). The primary endpoint was OS.
How long before venclexta can you do P-GP?from venclextahcp.com
Avoid concomitant use of VENCLEXTA with a P-gp substrate. If concomitant use is unavoidable, separate dosing of the P-gp substrate at least 6 hours before VENCLEXTA.
What is Venclexta Access Solutions?from genentech-access.com
For eligible patients with commercial or public health insurance, VENCLEXTA Access Solutions offers referrals to independent co-pay assistance foundations.*
How many patients were randomized in the Phase 3 trial of Venclexta?from news.abbvie.com
A total of 431 patients were randomized in the double-blind, placebo-controlled, multicenter, Phase 3 VIALE-A trial, which evaluated the efficacy and safety of VENCLEXTA in combination with azacitidine (n=286) in patients with AML who are ineligible for standard induction therapy versus azacitidine in combination with placebo (n=145). The primary endpoint was OS.
What are the side effects of venclexta?from news.abbvie.com
What are the possible side effects of VENCLEXTA?#N#VENCLEXTA can cause serious side effects, including: 1 Low white blood cell counts (neutropenia). Low white blood cell counts are common with VENCLEXTA, but can also be severe. Your healthcare provider will do blood tests to check your blood counts during treatment with VENCLEXTA and may pause dosing. 2 Infections. Death and serious infections such as pneumonia and blood infection (sepsis) have happened during treatment with VENCLEXTA. Your healthcare provider will closely monitor and treat you right away if you have a fever or any signs of infection during treatment with VENCLEXTA.
What is Venclexta used for?
VENCLEXTA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
How long before venclexta can you do P-GP?
Avoid concomitant use of VENCLEXTA with a P-gp substrate. If concomitant use is unavoidable, separate dosing of the P-gp substrate at least 6 hours before VENCLEXTA.
How long after last dose of Venclexta?
Advise females of reproductive potential to use effective contraception during treatment with VENCLEXTA and for at least 30 days after the last dose.
Does venetoclaxta increase TLS?
Concomitant use of VENCLEXTA with P-gp inhibitors or strong or moderate CYP3A inhibitors increases venetoclax exposure, which may increase the risk of TLS at initiation and during the ramp-up phase, and requires VENCLEXTA dose adjustment.
Does Venclexta cause renal failure?
Tumor lysis syndrome, including fatal events and renal failure requiring dialysis, has occurred in patients treated with VENCLEXTA. VENCLEXTA can cause rapid reduction in tumor and thus poses a risk for TLS at initiation and during the ramp-up phase in all patients, and during reinitiation after dosage interruption in patients with CLL/SLL.
Can you reduce the dose of Venclexta?
No dose adjustment is recommended for patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment.
Can Venclexta cause fetal harm?
VENCLEXTA may cause embryo-fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment and for at least 30 days after the last dose.
What is Venclexta used for?
VENCLEXTA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
How long before venclexta can you do P-GP?
Avoid concomitant use of VENCLEXTA with a P-gp substrate. If concomitant use is unavoidable, separate dosing of the P-gp substrate at least 6 hours before VENCLEXTA.
How long after discontinuation of Venclexta can you resume?
Resume the VENCLEXTA dosage that was used prior to concomitant use of a P-gp inhibitor or a strong or moderate CYP3A inhibitor 2 to 3 days after discontinuation of the inhibitor. Patients should avoid grapefruit products, Seville oranges, and starfruit during treatment as they contain inhibitors of CYP3A.
Can Venclexta cause fetal harm?
VENCLEXTA may cause embryo-fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment and for at least 30 days after the last dose.
Does Venclexta cause TLS?
VENCLEXTA can cause rapid reduction in tumor and thus poses a risk for TLS at initiation and during the ramp-up phase in all patients, and during reinitiation after dosage interruption in patients with CLL/SLL. Changes in blood chemistries consistent with TLS that require prompt management can occur as early as 6 to 8 hours following ...
Does a P-GP inhibitor increase the toxicities of Venclexta?
Concomitant use with a P-gp inhibitor or a strong or moderate CYP3A inhibitor increases VENCLEXTA exposure, which may increase VENCLEXTA toxicities, including the risk of TLS. Consider alternative medications or adjust VENCLEXTA dosage and monitor more frequently for adverse reactions.
Does Venclexta affect fertility?
Based on findings in animals, VENCLEXTA may impair male fertility.
Who provides free Venclexta?from genentech-access.com
The Genentech Patient Foundation provides free VENCLEXTA to people who don't have insurance coverage or who have financial concerns and to people who meet certain income criteria.*
What is a Venclexta access solution?from genentech-access.com
VENCLEXTA Access Solutions can refer you to the Genentech Oncology Co-pay Assistance Program. It can help you with the out-of-pocket costs for your Genentech medicine, if you’re eligible.
How long before venclexta can you do P-GP?from venclextahcp.com
Avoid concomitant use of VENCLEXTA with a P-gp substrate. If concomitant use is unavoidable, separate dosing of the P-gp substrate at least 6 hours before VENCLEXTA.
What is Venclexta used for?from venclextahcp.com
VENCLEXTA is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
How long after last Venclexta can you breastfeed?from venclextahcp.com
Advise nursing women not to breastfeed during treatment with VENCLEXTA and for 1 week after the last dose.
How long after a last dose of Venclexta can you use contraception?from gene.com
Advise females of reproductive potential to use effective contraception during treatment with VENCLEXTA and for at least 30 days after the last dose. Based on findings in animals, VENCLEXTA may impair male fertility.
How long does it take to stop Venclexta?from gene.com
Your healthcare provider may delay, decrease your dose, or stop treatment with VENCLEXTA if you have side effects. When restarting VENCLEXTA after stopping for 1 week or longer, your healthcare provider may again check for your risk of TLS and change your dose.
